NGNE · NASDAQ
Neurogene (NGNE) Stock Price & Fundamentals
Neurogene (NGNE) closed at $456.31 on Oct 9, 2026, up 0.35% from the previous close of $454.73.
Share price, past year
1Y +10.69%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $456.31 |
| Sep 30, 2026 | $472.50 |
| Aug 31, 2026 | $469.03 |
| Jul 31, 2026 | $485.66 |
| Jun 30, 2026 | $471.19 |
| May 29, 2026 | $472.96 |
| Apr 30, 2026 | $469.31 |
| Mar 31, 2026 | $462.76 |
| Feb 27, 2026 | $457.83 |
| Jan 30, 2026 | $446.30 |
| Dec 31, 2025 | $426.08 |
| Nov 28, 2025 | $413.58 |
| Oct 31, 2025 | $401.85 |
Key statistics
- Market cap
- $7.22B
- P/E (TTM)
- —
- EPS (TTM)
- −$5.03
- Revenue (TTM)
- —
- Net income (TTM)
- −$111.11M
- Shares outstanding
- 15.8M
- Dividend yield
- —
- 52-week range
- $381.88 – $501.48
Neurogene's market cap is $7.22B, based on a share price of $456.31 and 15.8M shares outstanding as of Jun 30, 2026.
Financials
Neurogene reported revenue of $0.00 for fiscal 2025, down 100.00% from fiscal 2024.
Neurogene reported a net loss of $90.35M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $0.00 | −100.0% | −$90.35M | — | −$4.24 | −$78.36M |
| FY2024ended Dec 31, 2024 | $925.00K | — | −$75.14M | −8,123.7% | −$4.28 | −$71.41M |
| FY2023ended Dec 31, 2023 | $0.00 | −100.0% | −$36.32M | — | — | −$51.74M |
| FY2018ended Dec 31, 2018 | $25.00M | — | −$31.59M | −126.3% | −$6.70 | −$31.63M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q3 FY2025ended Sep 30, 2025 | $0.00 | −$20.95M | −$0.99 |
| Q2 FY2025ended Jun 30, 2025 | $0.00 | −$22.02M | −$1.05 |
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$20.22M | −$1.19 |
| Q2 FY2024ended Jun 30, 2024 | $925.00K | — | — |
| Q3 FY2023ended Sep 30, 2023 | $0.00 | — | — |
| Q2 FY2023ended Jun 30, 2023 | $0.00 | — | — |
| Q2 FY2018ended Jun 30, 2018 | $25.00M | — | — |
Company profile
- Name
- Neurogene Inc.
- Ticker
- NGNE
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 535 W 24th Street, 5th Floor, New York, NY 10011
- Fiscal year ends
- December
- SEC CIK
- 0001404644
Recent SEC filings
- Aug 11, 2026
- Aug 11, 2026
- Jul 2, 2026
- Jun 29, 2026
- Jun 8, 2026
- Jun 4, 2026
- May 12, 2026
- May 12, 2026
Frequently asked questions
What is Neurogene's stock price?
Neurogene (NGNE) closed at $456.31 on Oct 9, 2026, up 0.35% from the previous close of $454.73.
What is Neurogene's market cap?
Neurogene's market cap is $7.22B, based on a share price of $456.31 and 15.8M shares outstanding as of Jun 30, 2026.
How much revenue does Neurogene make?
Neurogene reported revenue of $0.00 for fiscal 2025, down 100.00% from fiscal 2024.
Does Neurogene pay a dividend?
Neurogene's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Neurogene Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures